← The Wire
LONANasdaq
LeonaBio, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1620463
LeonaBio develops novel therapeutics for treatment-resistant metastatic breast cancer and ALS
$78M
Market cap
$8.86
Last close
-5.7%
1D
+7.1%
5D
20K
Volume
Price · last 39 sessions-7.2%
May 4L $7.88 · H $11.26Jun 29
124
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 23, 2026DEFA14ADEFA14AMay 11, 2026DEF 14ADEF 14AMay 11, 202610-Q10-QMay 7, 20268-KResults of Operations · Reg FD DisclosureMay 7, 2026SC 13D/ASC 13D/AMay 7, 2026S-1/AS-1/AMar 31, 2026S-1/AS-1/AMar 31, 202610-K10-KMar 31, 20268-K/AAcquisition / DispositionMar 31, 20268-KResults of Operations · Reg FD DisclosureMar 26, 20268-KExecutive Change · Shareholder VoteMar 19, 2026DEF 14ADEF 14AFeb 23, 2026SC 13D/ASC 13D/AJan 16, 20268-KExecutive Change · Bylaw AmendmentJan 9, 2026SC 13D/ASC 13D/ADec 23, 2025SC 13D/ASC 13D/ADec 22, 20258-K/AMaterial Agreement · Equity IssuanceDec 18, 20258-KMaterial Agreement · Equity IssuanceDec 18, 202510-Q10-QNov 6, 20258-KResults of Operations · Reg FD DisclosureNov 6, 20258-KCompany UpdateOct 3, 20258-KSecurity-Holder Rights · Bylaw AmendmentSep 11, 202510-Q10-QAug 7, 20258-KResults of Operations · Reg FD DisclosureAug 7, 20258-KShareholder VoteJun 2, 202510-Q10-QMay 9, 20258-KResults of Operations · Reg FD DisclosureMay 9, 20258-KDelisting NoticeApr 16, 2025DEFA14ADEFA14AApr 14, 2025DEF 14ADEF 14AApr 14, 202510-K10-KFeb 27, 20258-KResults of Operations · Reg FD DisclosureFeb 27, 202510-Q10-QNov 7, 20248-KResults of Operations · Reg FD DisclosureNov 7, 2024SC 13GSC 13GNov 7, 20248-KDelisting Notice · Company UpdateOct 18, 20248-KExecutive ChangeOct 7, 20248-KExecutive Change · Exit / Disposal CostsSep 17, 20248-KReg FD Disclosure · Company UpdateSep 3, 202410-Q/A10-Q/AAug 9, 202410-Q10-QAug 1, 20248-KResults of Operations · Reg FD DisclosureAug 1, 20248-KShareholder VoteMay 29, 20248-KCompany UpdateMay 17, 202410-Q10-QMay 15, 20248-KResults of Operations · Reg FD DisclosureMay 15, 2024DEFA14ADEFA14AApr 9, 2024DEF 14ADEF 14AApr 9, 202410-K10-KFeb 22, 20248-KExecutive Change · Results of OperationsFeb 22, 2024SC 13GSC 13GFeb 14, 20248-KExecutive Change · Results of OperationsJan 8, 202410-Q10-QNov 9, 20238-KResults of Operations · Reg FD DisclosureNov 9, 202310-Q10-QAug 10, 20238-KResults of Operations · Reg FD DisclosureAug 10, 20238-KExecutive Change · Shareholder VoteMay 22, 202310-Q10-QMay 11, 20238-KResults of Operations · Reg FD DisclosureMay 11, 2023SC 13GSCHEDULE 13GApr 20, 2023DEFA14AFORM DEFA14AApr 5, 2023DEF 14ADEF 14AApr 5, 202310-K10-KMar 23, 20238-KResults of Operations · Reg FD DisclosureMar 23, 20238-KMaterial Agreement · Results of OperationsJan 6, 2023424B5424B5Jan 6, 20238-KBylaw AmendmentNov 18, 202210-Q10-QNov 10, 20228-KResults of Operations · Reg FD DisclosureNov 10, 20228-KReg FD Disclosure · Company UpdateOct 17, 202210-Q10-QAug 15, 20228-KResults of Operations · Reg FD DisclosureAug 15, 20228-KReg FD Disclosure · Company UpdateJun 22, 20228-KShareholder VoteMay 24, 2022DEFA14ADEFA14AMay 17, 2022DEFA14ADEFA14AMay 17, 202210-Q10-QMay 12, 20228-KResults of Operations · Reg FD DisclosureMay 12, 2022DEFA14ADEFA14AMay 11, 2022
Insider Activity
In the 90 days to Mar 4, 2026: 5 sold $99K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Litton Mark JamesPRESIDENT and CEO | Sell | 5,156 | $5.37 | $28K |
| Mar 4, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sell | 1,720 | $5.37 | $9K |
| Mar 4, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Sell | 1,359 | $5.37 | $7K |
| Mar 4, 2026 | Worthington MarkGENERAL COUNSEL and CCO | Sell | 1,328 | $5.37 | $7K |
| Mar 4, 2026 | Renninger RobertCHIEF FINANCIAL OFFICER | Sell | 906 | $5.37 | $5K |
| Jan 2, 2026 | Litton Mark JamesPresident and CEO | Sell | 2,586 | $6.88 | $18K |
| Jan 2, 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sell | 1,644 | $6.88 | $11K |
| Jan 2, 2026 | Church KevinCHIEF SCIENTIFIC OFFICER | Sell | 876 | $6.88 | $6K |
| Jan 2, 2026 | Worthington MarkGeneral Counsel and CCO | Sell | 876 | $6.88 | $6K |
| Jan 2, 2026 | Renninger RobertChief Financial Officer | Sell | 297 | $6.88 | $2K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance